8-K: Vera Therapeutics Announces Positive Long-Term Data for Atacicept in IgAN, Advancing Towards Phase 3 Topline Results

Vera Therapeutics reported positive 96-week data from its Phase 2b ORIGIN trial of atacicept in IgAN, showing sustained reductions in key disease markers and stabilization of kidney function.

Summary

• Vera Therapeutics announced positive 96-week results from its Phase 2b ORIGIN clinical trial of atacicept for Immunoglobulin A Nephropathy (IgAN).
• The trial demonstrated a -66% reduction in galactose-deficient IgA1 (Gd-IgA1), a 75% resolution of hematuria, and a -52% reduction in proteinuria.
• Patients treated with atacicept showed a mean annualized estimated glomerular filtration rate (eGFR) slope of -0.6 mL/min/1.73m2/year, indicating stabilization of kidney function.
• The safety profile of atacicept remained consistent with previous observations, with a 90% completion rate of treatment.
• The company has approximately $353.2 million in cash, cash equivalents, and marketable securities as of September 30, 2024.
• Topline results from the Phase 3 ORIGIN 3 trial are expected in the second quarter of 2025, with a potential BLA submission in the second half of 2025 and a projected commercial launch in 2026.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results, a strong cash position, and clear plans for future development and commercialization, indicating a high level of confidence and potential for success.

Positives

• Atacicept showed significant reductions in key disease markers, including Gd-IgA1, hematuria, and proteinuria.
• The stabilization of eGFR suggests a potential disease-modifying effect of atacicept.
• The long-term safety profile of atacicept remained favorable.
• The high completion rate of 90% indicates good patient tolerability and adherence to treatment.
• The company has a strong cash position of approximately $353.2 million.
• The company is progressing towards a Phase 3 topline readout in Q2 2025 and a potential BLA submission in the second half of 2025.
• The company is planning to initiate the ORIGIN Extend study in Q4 2024 to provide extended access to atacicept to ORIGIN participants.
• The company is planning to initiate the PIONEER study in 2025 to evaluate the efficacy and safety of atacicept in expanded IgAN populations and other autoimmune glomerular diseases.

Negatives

• The cash balance of $353.2 million is preliminary and unaudited, subject to change upon completion of the financial close process.
• The company has not yet completed its quarter-end financial close process for the quarter ended September 30, 2024.
• The information presented should not be considered a substitute for the financial information the Company files with the SEC in its quarterly report on Form 10-Q for the quarter ended September 30, 2024.

Risks

• The preliminary cash balance is subject to change after the quarter-end financial close process.
• The results of earlier clinical trials may not be replicated in later trials.
• Regulatory approval is not guaranteed and is subject to various risks and uncertainties.
• The company's business is subject to general risks and uncertainties, including macroeconomic and geopolitical events.
• The company's forward-looking statements are based on current expectations and involve assumptions that may not materialize.

Future Outlook

The company anticipates topline results from the Phase 3 ORIGIN 3 trial in Q2 2025, with a planned BLA submission in the second half of 2025 and a potential commercial launch in 2026. They also plan to initiate the ORIGIN Extend study in Q4 2024 and the PIONEER study in 2025.

Management Comments

• Jonathan Barratt, MD, PhD, FRCP, stated that the data supports the potential of atacicept to modify the natural history of IgAN and prevent kidney failure.
• Marshall Fordyce, M.D., CEO of Vera Therapeutics, said that the stabilization of kidney function through two years positions atacicept as a potential bestand first-in-class treatment option for patients with IgAN.

Industry Context

The positive results for atacicept in IgAN are significant as there is a high unmet need for effective treatments for this disease. The data suggests that atacicept could be a potential best-in-class treatment, offering a new approach to managing IgAN by targeting B-cell activation. The company is also exploring the potential of atacicept in other autoimmune diseases, which could expand its market reach.

Comparison to Industry Standards

• The 96-week data for atacicept shows a mean annualized eGFR slope of -0.6 mL/min/1.73m2/year, which is a significant improvement compared to the natural progression of IgAN, which typically shows a decline of -4 to -8 mL/min/year.
• This result is also favorable when compared to other treatments for IgAN, such as endothelin receptor antagonists, which have shown an eGFR slope of around -3 mL/min/year, and SGLT2i and corticosteroids, which have shown an eGFR slope of around -4 to -5 mL/min/year.
• The data suggests that atacicept may offer a more effective approach to stabilizing kidney function in IgAN patients compared to existing therapies.
• The company is the only program with 2-year data in Phase 2, which is a significant differentiator.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and progress towards commercialization.
• Patients with IgAN may benefit from a new treatment option that could slow disease progression and prevent kidney failure.
• Employees may be motivated by the positive results and the company's progress.
• The company's success could lead to increased opportunities for suppliers and partners.

Next Steps

• The company will continue to advance the Phase 3 ORIGIN 3 clinical trial.
• Topline results from the Phase 3 ORIGIN 3 trial are expected in the second quarter of 2025.
• The company plans to submit a BLA for atacicept in IgAN to the U.S. FDA in the second half of 2025.
• The company plans to initiate the ORIGIN Extend study in Q4 2024.
• The company plans to initiate the PIONEER study in 2025.

Key Dates

Keywords

atacicept, IgAN, immunoglobulin A nephropathy, kidney disease, clinical trial, Phase 2b, Phase 3, eGFR, proteinuria, hematuria, B-cell modulator, autoimmune disease, biologics license application, BAFF, APRIL